Sarcopenia Is Not a Muscle Disease: The Case for Blaming Your Nervous System

#1

A five-author group including the National Institute on Aging’s Luigi Ferrucci argues that sarcopenia has been conceptually mislabeled for thirty years. The clinical definition already moved from low muscle mass to low strength and poor physical performance, but the underlying disease model stayed muscle-centric, and that mismatch explains why drug after drug has added lean tissue without adding function. The authors propose reframing sarcopenia as a disease of the entire ageing motor system, spanning motor cortex, spinal cord, motoneurons, peripheral nerves, neuromuscular junctions, proprioceptive afferents, and muscle. They offer a two-stage clinical pathway (a pragmatic motor-system-aware screen for everyone, mechanistic phenotyping only in specialist and trial settings) and a five-item research agenda.

For decades, the story of ageing muscle has been told as a story about muscle. Lose flesh, lose strength, lose independence. The trouble is that the arithmetic never worked.

Follow older adults for five years and their strength collapses two to five times faster than their muscle shrinks. In the Health ABC cohort, men aged 70 to 79 lost roughly 16 percent of knee extensor torque while losing only about 5 percent of thigh muscle area. More damaging still, people who gained muscle over those five years lost strength at essentially the same rate as everyone else. When researchers ask how much of the person-to-person variation in strength loss is explained by muscle loss, the answer is 6 to 8 percent. Ninety-plus percent of the phenomenon is coming from somewhere else.

That somewhere else, the authors argue, is the nervous system. Motoneurons degenerate, preferentially the large fast ones. Motor units remodel through repeated cycles of denervation and reinnervation. Persistent inward currents, the amplifiers that let a motoneuron sustain firing, weaken. Serotonin, noradrenaline, and dopamine projections thin out. Neuromuscular junctions fragment. Muscle spindles atrophy, so position sense degrades and movement becomes slow and cautious. Motor cortex excitability drops while inhibitory GABAergic tone rises. Weaker older adults show roughly a 20 percent deficit in voluntary activation compared with stronger peers of the same age, meaning they cannot fully recruit the muscle they already own.

This reframing has teeth because it predicts the field’s failures. If weakness is distributed across a chain, then loading one link, which is what anabolic drugs and protein supplements do, produces exactly what has been observed: mass goes up, function barely moves. It also explains why exercise keeps winning. Resistance and power training load muscle, drive neural adaptation, and improve mitochondrial function simultaneously.

The proposal is not that muscle stops mattering. It is that muscle is the effector, not the explanation. The authors go so far as to ask whether the word sarcopenia, literally poverty of flesh, should survive. Their practical demand is more modest: consensus bodies should redefine the disease, and the field should build cheap point-of-care tests that reveal which link in the chain is failing. Whether such tests beat a stopwatch and a grip dynamometer is, by the authors’ own admission, an open empirical question. [Confidence: High that the muscle-centric model underperforms; Medium that motor-system phenotyping will prove clinically actionable]

Actionable Insights

  1. Stop using muscle mass as your primary strength metric. Change in mass explains only 6 to 8 percent of the variation in strength loss (a weak correlation, roughly r = 0.25). Track strength, power, and gait speed instead.
  2. Adding mass does not rescue function. In a 1,678-person five-year cohort, people who gained weight and muscle area still lost knee extensor torque at 2.9 percent per year (men) and 1.9 percent per year (women), the same as everyone else.
  3. Train velocity, not just load. Power training beats conventional strength training for physical function with a standardized effect size of 0.30 (95 percent CI 0.05 to 0.54, 13 trials, 383 people). Translation: the average power-trained person outperforms about 62 percent of the strength-trained group, worth roughly 0.6 seconds on a timed up-and-go and half an extra chair stand. Real but small, and low certainty.
  4. Gait speed is the highest-yield number you can measure. Each 0.1 metre per second faster is associated with 12 percent lower mortality risk (hazard ratio 0.88, 95 percent CI 0.87 to 0.90, 34,485 adults). Five-year survival for men aged 75 to 84 ran from 57 percent (slowest) to 93 percent (fastest). Association, not proven causation.

Also worth auditing: sedative and anticholinergic medication burden, flagged as a reversible suppressor of motor drive.

Context and Source

  • Open Access Paper: Reframing sarcopenia as a disease of the ageing motor system
  • Authors: Lucas B R Orssatto, W David Arnold, Luigi Ferrucci, Marco V Narici, Brian C Clark
  • Article type: Personal View (expert opinion, not primary research)
  • Journal: The Lancet Healthy Longevity, 2026.
  • Institutions and countries: The University of Queensland, Brisbane, Australia; University of Missouri, Columbia, USA; National Institute on Aging, NIH, Baltimore, USA; University of Padova, Italy; Science and Research Centre Koper, Slovenia; Ohio University, Athens, USA.
  • Impact evaluation: The impact score of this journal is 20.5 (Journal Impact Factor; 5-year JIF 20.7; SJR 5.433, Q1; 97.2nd percentile in Geriatrics and Gerontology), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Related Reading:

5 Likes
#2

Many track mass, not because it’s better than strength, but because it’s easier to measure in some ways. Simple biomarkers often trump more accurate ones. BMI is the best example. Better biomarkers will help cure sarcopenia.

1 Like
#3

These generalizations comport with my personal aging experiences. While the entire process may be complex, my reading over the past few years suggests that “muscle loss” outcomes in aging can be explained as a combination of changes that take place in an overlapping sequence. Motor-unit attrition comes first. Large, motor neurons and axons are lost and the effects are disproportionately on Type II fibers. The motor units then compensate by developing collaterals (likely driven by chemical signals from muscles). The collaterals favor Type I fibers and therefore over time, Type II muscle is replaced by Type I muscle. I have definitely noticed this in the lower body muscle groups. The good news is that muscle quantity can remain surprisingly well preserved, which is what we see when octogenarians post pictures of their bulging bi- and triceps. These muscles may look the same as they did in youth and may have similar volume and decent strength but their compensation and functional performance is very different. Over time, some remaining neurons cannot rescue all newly denervated fibers and they shrink and ultimately disappear.

The received gero view on intervention is at least partially correct. Exercise reliably preserves strength, power and mobility, and can increase muscle mass even after age 85. What remains unproved is that exercise materially slows the actual death of spinal motor neurons. The principal perhaps sole benefit may be increasing the performance and compensatory capacity of the surviving neuromuscular system. There is no convincing evidence that exercise globally preserves motor-unit number. There is considerably better evidence that it increases motor-neuron excitability, improves voluntary recruitment, stimulated collateral reinnervation, enlarges surviving fibers, and Improves mitochondrial, capillary and metabolic function. Collectively, this forestalls frank sarcopenia.

There is much more to say on this but I will conclude with my current take on rapamycin where the first relevant human exercise trial can only be regarded as discouraging. Forty adults aged 65–85 received 6 mg weekly or placebo during 13 weeks of exercise. Rapamycin did not enhance chair-standing; the intention-to-treat difference favored placebo by 2.13 repetitions, and prespecified complete-case and per-protocol analyses significantly favored placebo. Adverse-event burden was also higher. There were limitations in this study, primarily related to length and design, but the interim conclusion has to be that there is presently no clinical basis for expecting rapamycin to protect muscle or augment exercise adaptation.

1 Like
Peptides / Bioregulators
#4

The problem with Brad Stanfields trial is that it did not properly recognise the way in which Rapamycin accentuates the catabolic phase. Doing this prevents to some extent anabolism whilst Rapamycin is active, but it causes more selective mitophagy which results in more efficient mitochondria. Because of the interplay between citrate efflux and gene expression more efficient mitochondria are needed for example to maintain a substantial neuronal (motor or dopaminergic) axonal arbour. (for the Americans and possibly not Canadians Arbor).

2 Likes